Condition (MeSH)
Flushing
ClinicalTrials.gov lists 19 trials for Flushing or a narrower condition beneath it. Merck Sharp & Dohme LLC has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 19 trials are tagged with Flushing itself; the rest are tagged with a narrower condition beneath it.
When did Flushing trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 1 |
| 2018 | 2 |
| 2014 | 1 |
| 2013 | 1 |
| 2009 | 5 |
| 2007 | 3 |
| 2004 | 2 |
| 2002 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Flushing trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 3 | 2 |
| Phase 4 | 3 |
| Not applicable | 5 |
| Observational | 3 |
How many Flushing trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 15 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Flushing trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 3 |
| Biogen | 1 |
| GlaxoSmithKline | 1 |
| Ipsen | 1 |
| NAOS Argentina S.A. | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Flushing? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Psyllium | 1 |
| Quercetin | 1 |
| Brimonidine | 1 |
| Dimethyl Fumarate | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| EC Aspirin | 3 |
| GSK256073A tablets + IR niacin tablets | 1 |
| MK0524A, /Duration of Treatment : 8 Weeks | 1 |
| Niacin and aspirin | 1 |
| Comparator: niacin / Duration of Treatment: 17 Weeks | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Flushing trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Urinary tract infection | 6 | 2 |
| Small intestinal obstruction | 4 | 1 |
| Abdominal pain | 2 | 1 |
| Hyperglycaemia | 2 | 2 |
| Kidney infection | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Flushing? (67)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea: A Nonrandomized Controlled Trial. | JAMA dermatology | 2024 | Yes |
| Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine: A Randomized Crossover Study. | Neurology | 2021 | Yes |
| Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan. | The Journal of investigative dermatology | 2021 | Yes |
| Effect of Topical Brimonidine on Alcohol-Induced Flushing in Asian Individuals: A Randomized Clinical Trial. | JAMA dermatology | 2020 | Yes |
| Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action. | Journal of the American Academy of Dermatology | 2020 | Yes |
Showing 5 of 67 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.